Joel Lavine

Professor of Pediatrics (tenured) Columbia University

Big picture

About Me

There are several moments in Dr. Joel Lavine's lengthy career that illustrate his abilities and place in the medical community that serve as a testament to that fact. Academically, he has concentrated on clinical research, clinical treatment, teaching and administration. People of any age who want to get into this industry might draw inspiration from his long and successful career.

He's worked on a wide range of things throughout his career, but his primary emphasis has been on figuring out how to employ cutting-edge technology to better understand and treat pediatric disorders that are exacerbated by underlying biological processes and diseases. As a result of his extensive and diverse research, he is recognized as a trailblazer in a wide variety of subjects.

When it comes to helping children and adults with obesity, he has spent the past two decades bringing together the fields of pediatrics, internal medicine, pathology, and radiology. Finding ways to assist persons with obesity better understand their body and the effect that obesity has on them is one of these themes. His scientific career has spanned more than four decades, yet he has just just begun.

Natural history and genetics, biomarker discovery, and therapy for nonalcoholic fatty liver disease (NAFLD) are among his key research interests. Few individuals are aware of the seriousness of this ailment or the extent to which it may harm the body. One in four persons in the United States has cirrhosis of the liver or other disorders related to this condition.

A Retrospective Study of Metabolic Liver Disease


According to Joel Lavine, Metabolic liver disease, also referred to as alcoholic hepatitis, is a liver disorder. It influences the process of removing toxins from the blood and aids the body's digestion of food. Depending on the cause, this disorder can be acquired or congenital. It could also be caused by an endocrine disorder or the failure of a metabolically important organ. The type of liver damage and the severity of the patient's illness will determine the treatment and outcome of this disease.

Despite widespread recognition of metabolic risk factor under-recording, the reasons for this remain unknown. Understanding the limitations of the International Classification of Diseases (ICD) codes can aid in the improvement of health-care database quality. ICD-10-AM codes for NAFLD and cirrhosis, for example, are highly specific but understate their prevalence by 42.9 percent. As a result, a retrospective study to determine the accuracy of the codes is required.

Joel Lavine explained that, ICD-10-CM K71.9 is billable for reimbursement purposes. This code's 2022 edition went into effect on October 1, 2021. It is required for reimbursement claims submitted after October 1, 2015.

The NAFLD/NASH ICD-10-AM codes were validated against the databases of two major Australian tertiary hospitals. To test the accuracy of the ICD-10-AM codes, data from patient encounters were compared to ICD-10-AM codes. In comparison to ALD, the ICD-10-AM codes had a high sensitivity and specificity. The ICD-10-AM codes had a high NPV and sensitivity, with a positive predictive value of 99.7 percent for each group of patients. Although there were five false positive codes, the overall results were favorable.

Joel Lavine revealed that, ICD-10-AM codes also enable us to investigate the prevalence of NAFLD/NASH cirrhosis in Australia. We can better plan our public health strategies and allocate resources with this information. However, there are still difficulties. Meanwhile, we can't ignore the fact that diagnosing NAFLD without adequate population-based data is impossible. And the advantages extend beyond the ICD-10-AM and ICD-10 codes.